Is bigger better? An argument for very low starting doses

Abstract

For years, we and others have advocated starting treatment of chronic indolent conditions at doses lower than those typically recommended in the product monographs.[1][1] The approach we recommend is to use a very low dose when starting a new medication if the condition is not life-threatening or